Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03798301 · ClinicalTrials.gov registry record · Phase 1
Treatment of Cytomegalovirus (CMV) Infections With Viral-Specific T Cells
A Phase 1 study, sponsored by University of Wisconsin, Madison.
- Terminated
- Registry status
- Phase 1
- Development phase
- 3
- Enrollment target
NCT03798301 is a Phase 1 study that was terminated before completion, run by University of Wisconsin, Madison. The registered enrollment target is 3 participants.
The verdict
NCT03798301, a Phase 1 study, was terminated before completion, sponsored by University of Wisconsin, Madison.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 3 participants
- Enrollment target
Study Summary
The present trial will consist of the treatment of 20 pediatric and adult Hematopoietic Stem Cell Transplantation (HSCT) recipients or immunocompromised participants diagnosed with opportunistic Cytomegalovirus (CMV) infections with virus-specific, antigen-selected T-cells. CMV-specific T-cells will be isolated from donor leukapheresis products using the CliniMACS® Prodigy. Prior studies on transfer of CMV specific T-cells have been shown to be safe and efficacious in the treatment of CMV infections. The main trial objective is to evaluate the feasibility and safety of CMV-specific T-cell transfer in adult and pediatric participants suffering from CMV infections or reactivation following HSCT or due to other immunocompromised states (e.g.; primary immunodeficiency, cytotoxic therapy). Participants will be followed for one year.
Interventions
- BIOLOGICAL CMV-specific T-cells
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2020-02-06 |
| Est. Completion | 2023-05-31 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03798301
The ClinicalTrials.gov registry entry for NCT03798301 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 3 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Wisconsin, Madison, which has 1,039 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which CMV-specific T-cells is the first listed.
NCT03798301 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03798301 about?
NCT03798301 is a clinical study titled "Treatment of Cytomegalovirus (CMV) Infections With Viral-Specific T Cells". The present trial will consist of the treatment of 20 pediatric and adult Hematopoietic Stem Cell Transplantation (HSCT) recipients or immunocompromised participants diagnosed with opportunistic Cytomegalovirus (CMV) infections with virus-specific, antigen-selected T-cells. CMV-specific T-cells will...
What is the current status of trial NCT03798301?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 3 participants. The study started on 2020-02-06. Estimated completion is 2023-05-31.
What interventions are being tested in trial NCT03798301?
The interventions under investigation include: CMV-specific T-cells (BIOLOGICAL).
Who is sponsoring clinical trial NCT03798301?
This trial is sponsored by University of Wisconsin, Madison, which has 1,039 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.